Keywords:
Upadacitinib, bDMARDs, tofacitinib, baricitinibReferences
Burmester GR, Rigby WF, van Vollenhoven R, Kay J, Rubbert-Roth A, Kroesen S, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rhe-um Dis. 2016;75(6):1081–91.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Wallenstein G, Kanik KS, et al. Filgotinib versus placebo and adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate (FINCH 1): a phase 3, randomised controlled trial. Ann Rheum Dis. 2021;80(7):848–58.
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from RA-BUILD, a phase 3 trial. Ann Rheum Dis. 2017;76(1): 88–95.
Fleischmann R, Pangan AL, Song I-H, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate (SELECT-COMPARE). Arthritis Rheumatol. 2019; 71(11):1788–800.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
Mease PJ, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous thromboembolism in patients with rheumatoid arthritis treated with tofacitinib, biologic, and conventional synthetic DMARDs: real-world evidence. Arthritis Rheumatol. 2020;72(11):1843–52.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68 (1):1–26.
Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias W, Rooney T, et al. Safety profile of baricitinib in patients with rheumatoid arthritis: integrated analysis of clinical trials up to 9.3 years. RMD Open. 2022;8(2):e002287.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):65 2–62.
van der Heijde D, Durez P, Schett G, Hui-zinga TWJ, Asquith D, Hodge J, et al. Upadacitinib in patients with rheumatoid arthritis and prior inadequate response to biologic DMARDs (SELECT-BEYOND): a phase 3, randomised controlled trial. Lancet. 2019;391(10139):2513–24.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.